



## ORIGINAL ARTICLE

# Antihistaminic and other biological activities of 2-methylpropanamide and benzamide derivatives of carboxyterfenadine



M. Saeed Arayne <sup>a,\*</sup>, Najma Sultana <sup>b</sup>, Hina Shehnaz <sup>c</sup>,  
Saf-ur-Rehman Mandukhail <sup>d</sup>, Anwarul Hassan Gilani <sup>d</sup>, Amir Haider <sup>a</sup>

<sup>a</sup> Department of Chemistry, University of Karachi, Karachi 75270, Pakistan

<sup>b</sup> Research Institute of Pharmaceutical Sciences, Faculty of Pharmacy, University of Karachi, Karachi 75270, Pakistan

<sup>c</sup> Department of Environmental Studies, Sind Madressatul Islam University, Karachi 74000, Pakistan

<sup>d</sup> Natural Product Research Division, Department of Biological and Biomedical Sciences, Aga Khan University Medical College, Karachi 74800, Pakistan

Received 19 November 2013; accepted 2 January 2015

Available online 23 January 2015

## KEYWORDS

Fexofenadine;  
Anticholinergic activity;  
Carboxyterfenadine

**Abstract** In the present study the 2-methylpropanamide and benzamide derivatives of carboxyterfenadine, have been synthesized by nucleophilic substitution at carboxylic acid moiety (C-33) of tertiary carbon C-19 substituted with benzene ring. The proficient and high yielding series was carried out in two steps by continuous monitoring with TLC. The carboxylic group was utilized in the formation of 2-methylpropanamide and benzamide derivatives of carboxyterfenadine. The derivatives were characterized by spectroscopic techniques including mass. The starting material (2-[4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidino]butyl]phenyl]-2-methylpropanoic acid) itself is H<sub>1</sub> receptor antagonist. Hence, all these compounds A–E were biologically evaluated for antihistaminic and anticholinergic activity, using isolated guinea pig ileum tissues.

© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

H<sub>1</sub> antagonists are the drugs that competitively inhibit the action of histamine on tissue containing H<sub>1</sub>. Usually H<sub>1</sub> receptors have been evaluated *in vitro* in terms of their ability to inhibit histamine induced spasms in an isolated strip of guinea pig ileum (Meeves and Appajosyula, 2003). Antihistamines may be assessed *in vivo* in terms of their ability to protect animals against the toxic effects of histamine administered intravenously or by aerosol (Suhagia et al., 2006; Saxena et al.,

\* Corresponding author.

E-mail addresses: [msarayne@gmail.com](mailto:msarayne@gmail.com) (M. Saeed Arayne), [hinashehnaz@gmail.com](mailto:hinashehnaz@gmail.com) (H. Shehnaz).

Peer review under responsibility of King Saud University.



Production and hosting by Elsevier




Figure 1 Fexofenadine.

2006). Fexofenadine (2-[4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidino]butyl] phenyl]-2-methylpropanoic acid) (Fig. 1) is a selective and peripherally acting  $H_1$ -receptor antagonist and is a non-sedative active metabolite of terfenadine (see Figs. 2 and 3).

It has a chiral carbon in its chemical structure and is orally administered as a racemic mixture of R- and S-enantiomers (Robbins et al., 1998), it has the capacity to exist as Zwitterionic form and does not cross blood-brain barrier (BBB) that is why it does not cause drowsiness or sedation (Lappin et al., 2010).

Fexofenadine is used clinically for treating seasonal allergic rhinitis (Segall et al., 2008) and daily 180 mg of the drug, given for 2 weeks caused statistical and clinical improvement in symptoms and less drowsiness in patients with modest to stern SAR (Hampel et al., 2003). The most common adverse events were headache, throat irritation, viral infection, nausea, dysmenorrhea, drowsiness, dyspepsia and fatigue (Markham and Wagstaff, 1998). Complex of fexofenadine with  $\alpha$ -cyclodextrin in aqueous medium was studied which gives the evidence of the attachment of phenyl ring into  $\alpha$ -cyclodextrin cavity (Ali et al., 2012). Thus, it is important to understand the mechanism of action of fexofenadine in the presence of chemically active compounds. Fexofenadine has poor bioavailability in humans and its microdose is used to predict the pharmacokinetics of the therapeutic drug because it has low intestinal membrane permeability due to hydrophilicity (Ohura et al., 2012).

*In vivo* and *in vitro* antihistaminic studies of fexofenadine have been established and oral administration on guinea pig indicates that fexofenadine antagonised histamine-induced skin wheals in a dose-dependent manner (Neuhaus et al., 2012; Malick and Grant, 1997). The isolated guinea pig ileum studies of fexofenadine and terfenadine reveal that both these compounds have antihistaminic property. Both drugs antagonised the contractile effects of histamine, although, fexofenadine is more selective anti-histamine than terfenadine (Zhang et al., 1994).

The present study uses fexofenadine as model compound and derivatives with hydrazine hydrochloride, urea, *p*-phenylenediamine, acetamide and semicarbazide have been prepared. In addition, the antihistaminic and anticholinergic activities of fexofenadine derivatives assessed and compared with fexofenadine and pyrilamine maleate taken as standard for the examination of biological activities.

The carboxylic group at tertiary carbon-19 through condensation reaction was esterified and by nucleophilic substitution reaction at the acyl (carbonyl) carbon form tetrahedral intermediate after the elimination of the leaving group it returns to a carbonyl carbon (Aryane et al., 2009). Various reactions have been recognized on the basis of the above reaction mechanism by reacting various amines to yield amides (Sultana et al., 2013).

## 2. Experimental

### 2.1. Material and equipments

Fexofenadine was a gift from Getz Pharmaceutical Laboratories Ltd., Karachi, Pakistan. Hydrazine hydrochloride, urea, *p*-phenylenediamine, acetamide and semicarbazide were of Merck, Darmstadt, Germany. Acetylcholine chloride (ACh), pyrilamine maleate, histamine diphosphate and potassium chloride were purchased from Sigma Chemicals Co, St Louis, MO, USA, magnesium chloride, magnesium sulfate, potassium dihydrogen phosphate, glucose, calcium chloride, sodium bicarbonate, sodium dihydrogen phosphate were purchased from E. Merck, Darmstadt, Germany and sodium chloride was purchased from BDH Laboratory Supplies, Poole, England. Analytical grade reagents were used and all the glassware was washed with chromic acid followed by a thorough washing with freshly prepared de-ionized water, freshly prepared salt solutions were used on the day of the experiment.

Melting points were obtained manually by capillary method. The IR spectra were obtained on Shimadzu prestige-21 200 VCE coupled to a PIV-PC and loaded with IR solution version 1.2 software (KBr disks). NMR spectra were recorded on Bruker FT-NMR 500 MHz with the compounds dissolved in deuterated methanol. Chemical shifts are reported in ( $\delta$  ppm) relative to tetramethylsilane as an internal standard. Significant  $^1H$  NMR data are tabulated in the order of multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; and m, multiplet) and number of protons. Mass spectra were recorded on Finnigan-MAT212 under electron impact (EI) ionization condition. Thin layer chromatography (TLC) was performed on HSF-254 TLC plate and compounds visualized under UV lamp. Tissue bath connected with thermocirculator which has an inlet and an outlet for salt solutions, tube for carbogen, finally connected with transducer, amplifier, oscillograph which monitors the tissue response on chart paper.

### 2.2. General procedure for preparation of derivatives

Synthesis of amide derivatives of fexofenadine with hydrazine hydrochloride, urea, *p*-phenylenediamine, acetamide and semicarbazide was carried out by adding 0.1 Mole fexofenadine in 60 mL of methanol with 1:2 drops of concentrated sulfuric acid and the whole content was refluxed for about 7–8 h. By continuous monitoring the flask contents, 0.2 M amine solutions were added individually into reaction flask and again refluxed for about 2–3 h till the completion of the reaction which was monitored by TLC. Excess solvent was removed by rotary evaporator and slowly crystallized out of the solution. The materials were recrystallized in suitable solvents till constant melting point.



sub-maximal concentration (0.3  $\mu$ M) of ACh with 3 min interval until constant responses were recorded.

## 2.5. Experimental protocol

After stabilization of the tissues, control peak responses of acetylcholine chloride (1  $\mu$ M) and histamine (1  $\mu$ M) were obtained and then these spasmogens were repeated in the presence of increasing concentrations of the compounds A–E (Willard et al., 1999; Gilani, 1992). Data were analyzed with Graphpad Prism version 5, GraphPad InStat 3 and expressed as means  $\pm$  SEM (Standard error of mean). One way ANOVA was used to compare the means between groups followed by Tukey's test for multiple comparisons.

## 2.6. Spectral data

**1-Fexofenadine:** 2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid, Color: white, m.p. 190 °C, UV nm ( $\epsilon$ ): 1.775(218 nm), IR (KBr) vmax: 3400–3350 db, s, 3058.04 s, 1700 s, 1600 and 1475 sm 1447.60 m, 1403.55 m, 1279 m, 1166.41 m, 1099 s, 1068 m, 983, 965 db, sm, 834 ms, 747, 702, 638, 577, 525.53 dp, s.  $^1$ H NMR (MeOD, 500 MHz)  $\delta$ : 7.06, 7.19 (m,  $J$  = 1.16 Hz), 7.11 (m,  $J$  = 0.5 Hz) aromatic, 4.5 (db,  $J$  = 1.0 Hz)  $-\text{CH}_2$  open chain, 4.95 (s) alcoholic, 2.0 N–H, 2.29, 2.19  $\text{CH}_2$ –N, 2.34 (t,  $J$  = 12.2 Hz)  $-\text{CH}_2$ – $\text{CH}_2$ –N, 2.36 (t,  $J$  = 14.0 Hz), 1.39, 1.77 and 1.52  $\text{CH}_3$ . MS ( $m/z$ , %): (500.29, 35.2%)  $\text{M}^+$ . Calculated for  $\text{C}_{32}\text{H}_{39}\text{NO}_4$ : C, 49.14; H, 5.96; N, 3.18. Found: C, 49.01; H, 5.74; N, 4.33.

**Compounds A to E:** 2-(A): 2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanamide, m.p. 115 °C, UV nm ( $\epsilon$ ): 171(223 and 259 nm), IR (KBr) vmax: 3350, 3100  $\text{cm}^{-1}$  (N–H), 1650  $\text{cm}^{-1}$  (C=O), 1390  $\text{cm}^{-1}$  (C–N).  $^1$ H NMR (MeOD, 500 MHz)  $\delta$ : 7.19 (m,  $J$  = 7.02 Hz), 7.11 (m,  $J$  = 3.5 Hz) and 7.06 aromatic, 6.92 (s, pri amide), 4.41 methine, 2.51, 2.41  $\text{CH}_2$ –N, 2.2(s) alcoholic, 1.77  $\text{CH}_3$ , 1.59, 1.3 (t,  $J$  = 6.2 Hz),  $\text{CH}_2$ – $\text{CH}_2$ –N. MS ( $m/z$ , %): (500, 9.2)  $\text{M}^+$ . Calculated for  $\text{C}_{32}\text{H}_{40}\text{N}_2\text{O}_3$ : C, 76.77; H, 8.05; N, 5.6. Found: C, 76.9; H, 7.99; N, 5.4.

**3-(B)  $N,N'$ -carbonylbis(2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanamide),** m.p. 120 °C, UV nm ( $\epsilon$ ): 2415 (223 and 259 nm), IR (KBr) vmax: 3380, 3180  $\text{cm}^{-1}$  (N–H), 1650  $\text{cm}^{-1}$  (C=O) 1622  $\text{cm}^{-1}$  (N–H bending), 1420  $\text{cm}^{-1}$  (C–N).  $^1$ H NMR (MeOD, 500 MHz)  $\delta$ : 9.6 (s, imide), 7.54 (m,  $J$  = 3.5 Hz), 7.38 (m,  $J$  = 7.02 Hz) and 7.28 aromatic, 3.9 methine, 3.6(s) alcoholic, 1.8  $\text{CH}_3$ , 2.5, 1.7  $\text{CH}_2$ –N, 1.4, 1.3 (t,  $J$  = 8 Hz)  $\text{CH}_2$ – $\text{CH}_2$ –N. MS ( $m/z$ , %): (1026.59, 7.9)  $\text{M}^+$ . Calculated for  $\text{C}_{65}\text{H}_{78}\text{N}_4\text{O}_7$ : C, 75.99; H, 7.65; N, 5.45. Found: C, 76.01; H, 7.69; N, 5.4.

**4-(C)  $N,N'$ -(1,4-phenylene)bis(2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanamide),** m.p. 229 °C, UV nm ( $\epsilon$ ): 5400 (223 and 259 nm), IR (KBr) vmax: 3390, 3130  $\text{cm}^{-1}$  (N–H), 1680  $\text{cm}^{-1}$  (C=O) 1640  $\text{cm}^{-1}$  (N–H bending), 1370  $\text{cm}^{-1}$  (C–N).  $^1$ H NMR (MeOD, 500 MHz)  $\delta$ : 8 (s, sec amide), 7.64 (m,  $J$  = 5.3 Hz), and 7.22 and 7.11 (m,  $J$  = 6 Hz) aromatic, 4.6 methine, 3.65(s) alcoholic, 2.75, 2.41  $\text{CH}_2$ –N, 1.6, 1.27 (t,  $J$  = 4.2 Hz)  $\text{CH}_2$ – $\text{CH}_2$ –N, 1.24  $\text{CH}_3$ . MS ( $m/z$ , %): (1074.62, 6.5)  $\text{M}^+$ .

Calculated for  $\text{C}_{70}\text{H}_{82}\text{N}_4\text{O}_6$ : C, 78.18; H, 7.69; N, 5.21. Found: C, 78.01; H, 7.61; N, 5.29.

**5-(D)  $N$ -carbamoyl-2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanamide,** m.p. 125 °C, UV nm ( $\epsilon$ ): 4090 (216 and 246 nm), IR (KBr) vmax: 3380, 3178  $\text{cm}^{-1}$  (N–H), 1600–1630  $\text{cm}^{-1}$  (C=O) 1625  $\text{cm}^{-1}$  (N–H bending), 1570  $\text{cm}^{-1}$  (C–N).  $^1$ H NMR (MeOD, 500 MHz)  $\delta$ : 8.8 (s, imide), 7.7 (m,  $J$  = 3.5 Hz), 7.46 (m,  $J$  = 7.02 Hz), 7.22 aromatic, 5.7 (s, urea) 3.7 methine, 3.2(s) alcoholic, 3.1, 2.6  $\text{CH}_2$ –N, 1.8  $\text{CH}_3$ , 1.6, 1.5 (t,  $J$  = 4.1 Hz)  $\text{CH}_2$ – $\text{CH}_2$ –N. MS ( $m/z$ , %): (586.32, 8.5)  $\text{M}^+$ . Calculated for  $\text{C}_{34}\text{H}_{42}\text{N}_4\text{O}_5$ : C, 69.60; H, 7.22; N, 9.55. Found: C, 69.4; H, 7.31; N, 9.71.


**6-(E)  $N$ -(2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoyl)benzamide,** m.p. 79 °C, UV nm ( $\epsilon$ ): 5740 (202 and 234 nm), IR (KBr) vmax: 3200, 3190  $\text{cm}^{-1}$  (N–H), 1620  $\text{cm}^{-1}$  (C=O), 1670  $\text{cm}^{-1}$  (N–H bending), 1545  $\text{cm}^{-1}$  (C–N).  $^1$ H NMR (MeOD, 500 MHz)  $\delta$ : 9.5 (s, imide), 8.08 aromatic, 7.28 (s,  $J$  = 3.5 Hz), 7.23 (s,  $J$  = 7.02 Hz), 2.1, 3.5  $\text{CH}_2$ –N, 2.32 methine, 3.65(s) alcoholic, 1.63, 1.58  $\text{CH}_3$ , 1.35 (t,  $J$  = 4.1 Hz)  $\text{CH}_2$ – $\text{CH}_2$ –N. MS ( $m/z$ , %): (604.33, 5.8)  $\text{M}^+$ . Calculated for  $\text{C}_{32}\text{H}_{44}\text{N}_2\text{O}_4$ : C, 77.45; H, 7.33; N, 4.63. Found: C, 77.20; H, 7.31; N, 4.38.

## 2.7. Spectral analysis


In the IR spectra of fexofenadine, the OH stretching vibration of carboxylic acid appeared as a broadband ranging from 3400 to 3350  $\text{cm}^{-1}$  and C–H stretching at 3058  $\text{cm}^{-1}$ , fexofenadine showed a strong band at 1700  $\text{cm}^{-1}$  due to C=O stretching and at 1279  $\text{cm}^{-1}$  for C–O stretching. C=C aromatic strong bands were observed at 1475 and 1600  $\text{cm}^{-1}$ , while in all compounds from A to E the hydroxyl peak of acid was modified and changed into broad to sharp band. The spectra of all the compounds showed the absence of acidic OH peak and amide has been formed.  $^1$ H NMR data supported the evidence of amide formation. The methyl groups of tertiary carbon and acidic proton have been shifted while other signals of fexofenadine were present. All compounds A to E showed a singlet in the region 6.9–9.5 ppm which provide evidence for the absorption of amide. In addition, the spectral data also mentioned other signals consequent to the particular chemical structure of the compounds. All the compounds showed very low percentage of ( $\text{M}^+$ ) peak because they were not as sturdy as fexofenadine. The electron impact mass spectrum (EIMS) of fexofenadine showed molecular ion ( $\text{M}^+$ ) peak at ( $m/z$ , %): (320, 35).

## 2.8. Effect on guinea-pig ileum

Fexofenadine a non-anticholinergic, non-sedative antihistamine (Caballero et al., 1996) is prescribed for oral treatment of allergic rhinitis and chronic urticaria (Amichai et al., 2001). The nonsedating fexofenadine is actually an active metabolite of terfenadine (Turncliff et al., 2006; Amon et al., 2000), a drug taken off the market because of its cardio toxicity. Recent data subjected to indicate whether the compounds A–E are antihistaminic and anticholinergic in nature or not. The Guinea pig ileum is commonly used to define whether a



**Figure 4** A tracing showing the inhibitory effect of 2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanamide.



**Figure 5** Inhibitory effect of histamine (1  $\mu$ M) responses in the presence of compound A–E on the guinea-pig ileum. Value shown are mean  $\pm$  S.E.M,  $n = 6$ . (\* $P < 0.05$ ; \*\* $P < 0.0001$ ; compared with control group; One way ANOVA, Tukey's multiple comparison).

potential drug has an antihistaminic effect (Larsson et al., 2007).

It is envisaged that all compounds are antihistaminic in nature but they did not block acetylcholine chloride (Fig. 4). The effect of different doses of fexofenadine was same to pyrillamine a standard histamine receptor ( $H_1$ ) antagonist for blocking the contractile effect of the guinea pig ileum while the acetylcholine chloride stimulant effects were not blocked (Corcóstegui et al., 2006).

In guinea-pig ileum, compounds A–E inhibit the histamine (1  $\mu$ M) responses at dose 3–100  $\mu$ M/mL (Fig. 4). Compound A: A dose of 3  $\mu$ M/ml  $81.67 \pm 3.827\%$ , 10  $\mu$ M/ml  $69.50 \pm 5.920\%$  and 30  $\mu$ M/ml  $47.00 \pm 4.382\%$  and complete inhibition obtained at a dose of 100  $\mu$ M/ml  $11.33 \pm 1.783$ . Compound B: A dose of 3  $\mu$ M/ml  $65.83 \pm 7.935\%$ , 10  $\mu$ M/ml  $53.00 \pm 3.759\%$  and 30  $\mu$ M/ml  $41.67 \pm 4.580\%$  and complete inhibition obtained at a dose of 100  $\mu$ M/ml  $12.67 \pm 2.728$  (see Fig. 5).

Compound **C**: A dose of 3  $\mu\text{M}/\text{ml}$   $69.00 \pm 11.60\%$ , 10  $\mu\text{M}/\text{ml}$   $54.50 \pm 8.094\%$  and 30  $\mu\text{M}/\text{ml}$   $45.00 \pm 2.933\%$  and complete inhibition obtained at a dose of 100  $\mu\text{M}/\text{ml}$   $15.17 \pm 3.978$ . Compound **D**: A dose of 3  $\mu\text{M}/\text{ml}$   $70.83 \pm 10.85\%$ , 10  $\mu\text{M}/\text{ml}$   $57.17 \pm 5.700\%$  and 30  $\mu\text{M}/\text{ml}$   $45.00 \pm 4.494\%$  and complete inhibition obtained at a dose of 100  $\mu\text{M}/\text{ml}$   $18.00 \pm 4.258$ . Compound **E**: A dose of 3  $\mu\text{M}/\text{ml}$   $74.83 \pm 2.833\%$ , 10  $\mu\text{M}/\text{ml}$   $54.17 \pm 3.978\%$  and 30  $\mu\text{M}/\text{ml}$   $36.83 \pm 3.016\%$  and complete inhibition obtained at a dose of 100  $\mu\text{M}/\text{ml}$   $18.00 \pm 4.258$ . And its parent compound fexofenadine cause inhibition of histamine (1  $\mu\text{M}$ ) responses at dose 0.000003  $\mu\text{M}/\text{ml}$   $23.14 \pm 4.48$ , 0.00001  $\mu\text{M}/\text{ml}$   $40.87 \pm 8.98$ , 0.00003  $\mu\text{M}/\text{ml}$   $51.87 \pm 11.74$ , 0.0001  $\mu\text{M}/\text{ml}$   $89.05 \pm 1.28$  and 0.0003  $\mu\text{M}/\text{ml}$  cause complete inhibition. Similar patterns of inhibition were seen with pyrilamine at dose 0.03  $\mu\text{M}/\text{ml}$   $13.52 \pm 7.83\%$ , 0.1  $\mu\text{M}/\text{ml}$   $70.96 \pm 7.05\%$ , 0.3  $\mu\text{M}/\text{ml}$   $88.69 \pm 1.84\%$  and the 1.0 show the complete inhibition of histamine (1  $\mu\text{M}$ ) responses.

### 3. Conclusion

The current study was the first attempt in which five derivatives (2-methylpropanamide and benzamide) of fexofenadine were synthesized, characterized by TLC, IR, UV, NMR and mass spectroscopy. The antihistaminic and anticholinergic mechanisms were tested on guinea pig ileum. The compounds **A–E** have antihistaminic action but not anticholinergic as shown by the tissue response.

### References

- Ali, S.M., Khan, S., Crowyn, G., 2012. Structure determination of fexofenadine- $\alpha$ -cyclodextrin complex by quantitative 2D ROESY analysis and molecular mechanics studies. *Magn. Reson. Chem.* 50 (4), 299–304. <http://dx.doi.org/10.1002/mrc.3807>, Epub 2012 Mar 14. <<http://www.ncbi.nlm.nih.gov/pubmed/22416034>>.
- Amichai, B., Grunwald, M.H., Brenner, L., 2001. Fexofenadine hydrochloride – a new anti-histaminic drug. *Isr. Med. Assoc. J.* 3 (3), 207–209, <<http://www.ima.org.il/IMAJ/ViewJournal.aspx?JournalId=142>>.
- Amon, U., Amon, S., Gibbs, B.F., 2000. In vitro studies with fexofenadine, a new non sedating histamine H1 receptor antagonist, on isolated human basophils. *Inflamm. Res.* 49 (Suppl 1), S13–S14, <<http://www.ncbi.nlm.nih.gov/pubmed/10864400>>.
- Arayne, M.S., Sultana, N., Haroon, U., Mesaik, M.A., Asif, M., 2009. Synthesis and biological evaluations of enoxacin carboxamide derivatives. *Arch. Pharm. Res.* 32 (7), 967–974. <http://dx.doi.org/10.1007/s12272-009-1700-5>, <<http://www.ncbi.nlm.nih.gov/pubmed/19641876>>.
- Caballero, E., Ocaña, I., Azanza, J.R., Sádaba, B., 1996. Fexofenadine: a antihistaminic. Review of its practical characteristics. *Rev. Med. Univ. Navarra.* 43 (2), 93–97, <<http://www.ncbi.nlm.nih.gov/pubmed/11256010>>.
- Corcóstegui, R., Labeaga, L., Innerarity, A., Berisa, A., Orjales, A., 2006. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. *Drugs R and D* 7 (4), 219–231, <<http://link.springer.com/article/10.2165/00126839-200607040-00002>>.
- Gilani, A.H., 1992. *Fitoterapia* 63, 237–242, <<http://www.aku.edu/collegeschoolsandinstitutes/medicine/pakistan/departments/biologicalandbiomedicalsciences/research/researchgroups/Pages/gilanipublications.aspx>>.
- Hampel, F., Ratner, P., Mansfield, L., Meeves, S., Liao, Y., Georges, G., 2003. Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. *Ann. Allergy Asthma Immunol.* 91 (4), 354–361, <<http://www.ncbi.nlm.nih.gov/pubmed/14582814>>.
- Lappin, G., Shishikura, Y., Jochemsen, R., Weaver, R.J., Gesson, C., Houston, B., Oosterhuis, B., Bjerrum, O.J., Rowland, M., Garner, C., 2010. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. *Eur. J. Pharm. Sci.* 40, 125–131, <<http://www.ncbi.nlm.nih.gov/pubmed/20307657>>.
- Larsson, A.K., Fumagalli, F., DiGennaro, A., Andersson, M., Lundberg, J., Edenius, C., Govoni, M., 2007. A new class of nitric oxide-releasing derivatives of cetirizine: pharmacological profile in vascular and airway smooth muscle preparations. *Br. J. Pharmacol.* 151, 35–44. <http://dx.doi.org/10.1038/sj.bjp.0707214/pdf>, <<http://onlinelibrary.wiley.com/>>.
- Malick, A., Grant, J.A., 1997. Antihistamines in the treatment of asthma. *Allergy* 52 (34 Suppl), 55–66. <http://dx.doi.org/10.1111/j.1398-9995.1997.tb04812.x/abstract>, <<http://onlinelibrary.wiley.com/>>.
- Markham, A., Wagstaff, A.J., 1998. Fexofenadine *Drugs* 55 (2), 269–274, discussion 275–6. <<http://www.ncbi.nlm.nih.gov/pubmed/9506246>>.
- Meeves, S.G., Appajosyula, S., 2003. Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment. *J. Allergy Clin. Immunol.* 112, S69–S77, <<http://download.journals.elsevierhealth.com/pdfs/journals/0091-6749/PIIS0091674903022188.pdf>>.
- Neuhaus, W., Mandikova, J., Pawlowitsch, R., Linz, B., Bennani-Baiti, B., Lauer, R., Lachmann, B., Noe, C.R., 2012. Blood-brain barrier in vitro models as tools in drug discovery: assessment of the transport ranking of antihistaminic drugs. *Pharmazie* 67 (5), 432–439. <http://dx.doi.org/10.1691/ph.2012.1742>, <[http://pharmazie.govi.de/contents\\_0512.htm](http://pharmazie.govi.de/contents_0512.htm)>.
- Office of Laboratory Animal Welfare, 2002. In Public Health Service Policy on Humane Care and Use of Laboratory Animals. Washington D.C: The National Academies Press. <<http://grants.nih.gov/grants/olaw/Guide-for-the-care-and-use-of-laboratory-animals.pdf>>.
- Ohura, K., Soejima, T., Nogata, R., Adachi, Y., Ninomiya, S., Imai, T., 2012. Effect of intestinal first-pass hydrolysis on the oral bioavailability of an ester prodrug of fexofenadine. *J. Pharm. Sci.* 101 (9), 3264–3274. <http://dx.doi.org/10.1002/jps.23182>, <<http://www.ncbi.nlm.nih.gov/pubmed/22628163>>.
- Robbins, D.K., Castles, M.A., Pack, D.J., Bhargava, V.O., Weir, S.J., 1998. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. *Biopharm. Drug Dispos.* 19 (7), 455–463, <<http://www.ncbi.nlm.nih.gov/pubmed/9818712>>.
- Saxena, M., Gaur, S., Prathipati, P., Saxena, A.K., 2006. Synthesis of some substituted pyrazinopyridoindoles and 3D QSAR studies along with related compounds: piperazines, piperidines, pyrazinoisoquinolines, and diphenhydramine, and its semi-rigid analogs as antihistamines H<sub>1</sub>. *Bioorg. Med. Chem.* 14 (24), 8249–8258, <<http://www.sciencedirect.com/science/article/pii/S0968089606007498>>.
- Segall, N., Grubbe, R.E., Levy, A.L., Maloney, M.J., Nayak, A.S., Kittner, B., Quesada, J.T., 2008. Pharmacokinetics, safety and tolerability of an oral suspension of fexofenadine for children with allergic rhinitis. *Allergy Asthma Proc.* 29 (4), 380–385. <http://dx.doi.org/10.2500/aap.2008.29.3136>, <<http://www.ncbi.nlm.nih.gov/pubmed/18702885>>.
- Suhagia, B.N., Chhabria, M.T., Makwana, A.G., 2006. Design, synthesis and pharmacological screening of a series of N1-(substituted) aryl-5,7-dimethyl-2-(substituted)pyrido(2,3-d)-pyrimidin-4(3H)-ones as potential histamine H<sub>1</sub> receptor antagonists. *J. Enzyme. Inhib. Med. Chem.* 21 (6), 681–691, <<http://informa-healthcare.com/doi/pdfplus/10.1080/14756360600851104>>.

- Sultana, N., Arayne, M.S., Naz, A., Msaik, M.A., 2013. Identification of anti-inflammatory and other biological activities of 3-carboxamide 3-carbohydrazide and ester derivatives of gatifloxacin. *Chem. Cent. J.* 14 (1), 6. <http://dx.doi.org/10.1186/1752-153X-7-7>, 7. <<http://journal.chemistrycentral.com/content/7/1/6>>.
- Turncliff, R.Z., Hoffmaster, K.A., Kalvass, J.C., Pollack, G.M., Brouwer, K.L., 2006. Hepatobiliary disposition of a drug/metabolite pair: comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes. *J. Pharmacol. Exp. Ther.* 318 (2), 881–889, <<https://www.pubmed.com/pubmed/?term=%20Hepatobiliary%20disposition%20of%20a%20drug/metabolite%20pair%20Comprehensive%20pharmacokinetic%20modeling%20in%20sandwich-cultured%20rat%20hepatocytes>>.
- Willard, H.H., Mervitt, L.L., Jr., Dean J.A., Settle, F.A., 1999. *Instrumental Methods of Analysis*, Wadsworth Publishing Company Belmont California., seventh ed., 287. <<http://www.gobooks.org/instrumental-methods-of-analysis-by-willard/>>.
- Zhang, M.Q., Caldirola, P., Timmerman, H., 1994. Chiral manipulation of Drug Selectivity: Studies on a Series of Terfenadine-Derived Dual Antagonists on H1-Receptors and Calcium Channels. *Agents Actions.* 41, Spec No., C140-2. <<http://www.ncbi.nlm.nih.gov/pubmed/7976802>>.